Medicament composition containing drynaria and salvia root, and use thereof

Abstract

The invention relates to a medicine composition for treating osteoporosis, in particular to the medicine composition of rhizoma drynariae and radix salviae miltiorrhizae, and medicinal application thereof. The weight ratio of the rhizoma drynariae to the radix salviae miltiorrhizae is 1:0.2-10. Main active ingredients in the extract of the composition are a flavonoid compound from rhizoma drynariae, a diterpenoid tanshinone compound from radix salviae miltiorrhizae and a salvianolic acid compound, wherein contents of the three active ingredients, namely total flavonoids from the rhizoma drynariae, tanshinone and salvianolic acids, are not lower than 40 percent of total weight of the extract. The extract of the composition can effectively avoid reduction of rat bone density caused by retinoic acid, has the remarkable effect of promoting blood circulation by removing blood stasis, and can be used for preparing the medicine for preventing and treating the osteoporosis. The traditional Chinese medicine composition has the advantages of simple formulation, high content of effective ingredients, controllable quality, safety and efficiency.

Description

Technical field: [0001] The invention relates to a pharmaceutical composition for treating osteoporosis, in particular to the pharmaceutical composition of Rhizoma Drynariae and Salvia Miltiorrhiza and its medical application. Background technique: [0002] Osteoporosis is a kind of disease characterized by decreased bone mass, abnormal microstructure of bone tissue and increased risk of fracture. It is common in the elderly, especially postmenopausal women, with a high incidence and great harm. With the aging of the global population, the status of osteoporosis in the world's common diseases and frequently-occurring diseases has gradually risen to the seventh place, and the number of patients has exceeded 200 million, and my country has reached 90 million. The global cost of treating osteoporosis and its associated complications exceeds US$25 billion. At present, western medicines for the treatment of this disease mainly include estrogen, calcium, calcitonin, bisphosphonat...

AI Technical Summary

Problems solved by technology

Traditional Chinese patent medicines such as Gusongbao Tablets, Gusongkang Mixture, Liuwei Zhuanggu Granules, Shengusan, Xianling Gubao, etc., have certain curative advantages based on the concept of overall regulation in traditional Chinese medicine, but some of these medicines have inconvenient dosage forms Portable or inconvenient to take, some have a lot of medicinal taste and take a large dose, some have less active ingredients, and the quality control standard is low, so sometimes it is difficult to obtain satisfactory clinical curative effect

Modern traditional Chinese medicines, such as drynaria total flavonoids, come from a single effective component, which has clear ingredients, precise efficacy, and controllable quality, but has a single effect, which fails to reflect the concept of overall regulation in traditional Chinese medicine, and has no obvious advantages in clinical efficacy

Images